FOR IMMEDIATE RELEASE
March 15, 2013
SymBio Pharmaceuticals Limited
Eisai Co., Ltd.

SYMBIO AND EISAI ANNOUNCE REMOVAL OF TREAKISYM® INJECTION 100 MG
ALL CASES SURVEILLANCE CONDITION FOR JAPAN MARKETING APPROVAL

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida,“SymBio”) and Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”)
announced today that they have received notification from the Japanese Ministry of Health, Labour andWelfare (MHLW) informing the companies that the condition for TREAKISYM® (bendamustinehydrochloride) marketing approval, All Cases Surveillance,*1 has been lifted in Japan.
In October 2010, SymBio received marketing approval from the MHLW for TREAKISYM® to treat
Japanese patients with relapsed/refractory low-grade non-Hodgkin’s lymphoma*2 (LG-NHL) and mantle
cell lymphoma (MCL), and the agent has been marketed by Eisai in Japan since its launch inDecember 2010, based on an ongoing license agreement between SymBio and Eisai. The original
condition for approval by the MHLW stated that due to the very limited number of subjects treated indomestic clinical trials, post-marketing surveillance of all patients who receive TREAKISYM® should be
carried out until data for a certain number of patients has been collected in order to identify patient
background as well as early safety and efficacy data, and necessary measures for the proper use ofTREAKISYM®.
Safety data for 583 patients, and efficacy data for 497 patients, was submitted to the MHLW as ananalysis of data collected during post-marketing surveillance*3. Based on this analysis, MHLW
concluded that post-marketing surveillance had been conducted properly with necessary measures forproper use of the drug in place, and accordingly, no further surveillance is required.
As part of the life cycle management of the agent, the development of TREAKISYM® for otherindications is underway in Japan, including a Phase 2 study in primary LG-NHL and MCL. Bothcompanies will work closely together in an effort to meet unmet medical needs and continue to expedite
development of TREAKISYM so as to provide the drug as early as possible to patients who need it.
[Please read the following for further information on terms *1 to *3, TREAKISYM® (Bendamustinehydrochloride) including a product outline, and corporate profile of SymBio and Eisai]Media Inquiries
Corporate Planning Department
SymBio Pharmaceuticals Limited
Tel: +81-3-5472-1125

Public Relations Department
Eisai Co., Ltd.
Tel: +81-3-3817-5120

[Notes to Editors]
1. About the All Cases Surveillance
The All Cases Surveillance collected data on use results concerning the safety and efficacy ofTREAKISYM® in patients with relapsed/refractory low-grade non-Hodgkin’s lymphoma or mantle celllymphoma in Japan. The data was collected in order to understand the following objectives:(1) Expression of side effects(2) Factors thought to influence safety, efficacy, and related issues(3) Other major points of focus of the surveillance (severe infection, tumor lysis syndrome, severe skindisorders, and expression of hypersensitivity reactions)
2. About Non-Hodgkin’s Lymphoma (NHL)Non-Hodgkin’s lymphomas (NHLs) are a diverse group of blood cancers that include any kind oflymphoma, which is a kind of white blood cell, with the exception of Hodgkin’s lymphomas, andcomprises the majority of lymphoma cases in Japan. NHLs are often classified into two groups basedon their progression rate: slow-growing NHLs whose progression is measured in years are classified as
low-grade (LG), while those whose progression is measured in months are classified as intermediateor high-grade (Aggressive) NHLs. There are an estimated 11,000 patients with LG-NHL in Japan. Of
this number, 4,000 are believed to be patients with relapsed/refractory LG-NHL and 7,000 to be patientswith primary LG-NHL.
3. About the Analysis of the All Cases SurveillanceAccording to the results of the analysis, side effects were reported in 564 cases out of a total of 583
cases analyzed in terms of patient safety, with the incidence rate at 96.74%. The main side effects werelymphopenia at 71.87%, leukopenia at 57.46%, neutropenia at 55.57%, thrombocytopenia at 40.14%,
anemia at 19.55%, and nausea at 19.21%. These side effects were consistent with outcomes reported
for clinical trials carried out overseas to date as well as trials conducted in Japan at the time ofdevelopment.
4. About TREAKISYM® (Bendamustine hydrochloride)
Bendamustine hydrochloride was first synthesized in the former East Germany by Jenapharm and iscurrently marketed in Europe under the brand name Ribomustin® or Levact® as a treatment for
non-Hodgkin’s lymphoma, multiple myeloma and chronic lymphocytic leukemia. In the United States,
the drug is marketed as TREANDA® for the treatment of chronic lymphocytic leukemia andrelapsed/refractory B-cell non-Hodgkin's lymphoma.
In December 2005, SymBio Pharmaceuticals acquired the exclusive right to develop andcommercialize the agent, as its first developmental drug, in Japan, China including Hong Kong, Taiwan,South Korea and Singapore from Astellas Deutschland GmbH. Based on a sublicensing agreementwith SymBio, Eisai acquired co-development and exclusive marketing rights in Japan and exclusive
development and marketing rights in South Korea and Singapore in May 2009. SymBio granted
exclusive development and marketing rights in China including Hong Kong based on a licensing
agreement with Cephalon, Inc. (currently Teva Pharmaceutical Industries Ltd.) in March 2009. (Thedevelopment and marketing rights for bendamustine hydrochloride are held by Teva PharmaceuticalIndustries Ltd. in North America, Mundipharma International Ltd. in Europe, and Janssen-Cilag Ltd. inother regions.)5. About TREAKISYM® Product Outline
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochloride
Indications and Usage:
For the treatment of relapsed/refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused intravenously over 60
minutes on Days 1 and 2 of repeated 21-day cycles. The dose may be reduced as deemed appropriate
according to the patient’s condition.
6. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously
served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan (currentlyTakeda Bio Development Center Limited). The company’s underlying corporate mission is “delivering
hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacificdedicated to addressing underserved medical needs with a focus in oncology, hematology andautoimmune disease.
7. About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based pharmaceutical company that discovers, develops and markets
products worldwide. Guided by its corporate mission of “giving first thought to patients and their families,
and to increasing the benefits that healthcare provides,” all Eisai employees aspire to meet the various
needs of global healthcare as representatives of a “human health care (hhc) company” that is capableof making a meaningful contribution under any healthcare system. For more information about EisaiCo., Ltd., please visit www.eisai.com.